The short answer
Adult obesity trials report percentage change in body weight. Trials in children and adolescents report percent change in body mass index instead, because a growing participant can gain height and weight simultaneously while their adiposity falls.
Key facts
- Adult endpoint
- Percent change in body weight
- Paediatric endpoint
- Percent change in BMI
- Reason
- Height is still increasing
- Registry example
- NCT06075667 primary outcome is BMI
- Assessment standard
- Growth reference percentiles
- Known measurement problem
- z-scores compress above the 95th percentile
Why body weight is the wrong endpoint in a growing person
An adolescent who grows several centimetres over a 68-week trial should gain some weight. Measuring success as weight reduction would penalise normal growth and reward its absence, which is the wrong incentive. BMI accounts for height, so it can fall while absolute weight holds steady or rises.
How obesity is defined differently in children
Adults are assessed against fixed BMI thresholds. Children are assessed against growth reference charts, because normal BMI varies substantially with age and sex through childhood. A child is classified by where they sit relative to a reference population of the same age and sex, commonly at or above the 95th percentile.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The measurement problem that follows
The natural way to express position on a growth chart is a z-score, the number of standard deviations from the reference mean. But the distribution is highly skewed at the upper end, so z-scores compress severely above the 95th percentile. A large change in actual BMI produces a small change in z-score. Wei and colleagues addressed exactly this in the Annals of Human Biology in 2020, publishing a method for calculating z-scores and percentiles above the 95th percentile.
Why that matters for trials specifically
Severe paediatric obesity sits in the compressed region. A trial reporting change in z-score would understate a real effect, and two trials using different handling of the upper tail would not be comparable. Reporting percent change in BMI avoids the compression entirely, which is why registered trials use it, NCT06075667 lists its primary outcome as percent change from baseline in body mass index.
What this means for reading a headline
A paediatric figure and an adult figure are not the same measurement. STEP TEENS reported a 16.1% mean change in BMI; adult semaglutide trials report percentage weight loss. Setting those numbers beside each other as though they described the same thing is a category error, and it happens routinely.
What this site is and is not describing
Registered clinical trials in defined paediatric populations, conducted under clinical supervision with ethics approval and specialist oversight. Nothing supplied here is a licensed medicine, is related to any of these compounds, or has any place in the care of a child.
Quick reference
| Adult trials | Paediatric trials | |
|---|---|---|
| Primary endpoint | % change in body weight | % change in BMI |
| Obesity defined by | Fixed BMI thresholds | Growth reference percentile |
| Complication | - | z-score compression above 95th centile |
Frequently asked questions
Why don't paediatric trials report weight loss?
Because participants are still growing. Measuring weight reduction would penalise normal growth and reward its absence.
What is z-score compression?
The BMI distribution is highly skewed at the top, so above the 95th percentile a large change in real BMI produces only a small change in z-score.
Can I compare a paediatric figure with an adult one?
No. One is percent change in BMI, the other percent change in body weight. They are different measurements.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedWei R et al., A method for calculating BMI z-scores and percentiles above the 95th percentile of the CDC growth charts. Ann Hum Biol 2020 (PMID 32901504)pubmed.ncbi.nlm.nih.gov
- PubMedWeghuber D et al., Once-Weekly Semaglutide in Adolescents with Obesity. NEJM 2022 (PMID 36322838)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Tirzepatide once weekly in adolescents with obesity or overweight (NCT06075667)clinicaltrials.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- STEP TEENS and What It Reported201 adolescents, 68 weeks, −16.1% BMI against +0.6% on placebo. The full result including the safety findings that get left out.
- What Is Actually Registered, and at What PhaseA Phase 3 in 160 adolescents aged 12-17, and a Phase 1 safety study in 28 children aged 6-11. The distinction matters for what results will mean.
- When Low Muscle and High Fat Occur TogetherA 2026 paper describes sarcopenic obesity in children using clinical data and a juvenile mouse model. Why the body composition question is sharper in the young.
- Slowing the Stomach Changes When a Tablet ArrivesMost oral drugs are absorbed in the small intestine, so gastric emptying controls when absorption starts. Slowing it flattens the concentration peak.
- One Compound, Not the Whole ClassTirzepatide reduced peak contraceptive hormone concentrations by 55-66% in reported data. Semaglutide, liraglutide and dulaglutide did not show the effect.